

Sector Vector Newsletter Advertising Opportunities



Key Metrics

*Average of issues Jan-Dec 2023



17,000+
subscribers



33%
average open rate*




8.5%
average click rates*




25%+
recipients are executive
leaders

Executive Leadership
(Common titles: CEO, COO, VP)



Audiences



ADVERTISING OPTIONS

▶ Banner Placement – Top

Hyperlinked advertisement and summary description (25 words or less).
Placement Bundles (subject to availability):




▶ Banner Placement – Middle

Hyperlinked banner advertisement
Placement Bundles (subject to availability):



▶ Banner Placement – End

Hyperlinked banner advertisement Placement Bundles (subject to availability):



▶ Job Postings (Maximum 8 weeks)

Member Rate: → **\$150**
per job posting per week

Non-Member Rate: → **\$200**
per job posting per week

AD PLACEMENTS

View this email in your browser

Alliance for Regenerative Medicine

THE SECTOR VECTOR

Delivering the latest news in gene therapy, cell therapy, & tissue engineering

May 15, 2024



Join the **World's Largest Orphan Drug and Rare Disease Event** as we cover the start-to-finish of orphan drugs, from regulation and policy to global pricing and gene therapy.

Business

Bluebird bio announces first patient's cells collected for LYFGENIA and that 14 patient scans were completed for ZYNTEGLO and SKYSONA since the beginning of 2024 - May 9

Inovance Biotherapeutics Updates That More Than 100 Patients Have Enrolled for Its Arragui Cell Therapy Since FDA Approval - May 9

Dyno Therapeutics to Accelerate Design of High-Performance Biological Sequences Using NVIDIA AI - May 9

Arbor Biotechnologies Announces Acquisition of Serendipity - May 8

Astellas Unveils New, State-of-the-Art, \$90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor - May 8

Caring Cross and ImmunoAdoptive Cell Therapy (ImmunoACT) Announce Agreement to Commercialize TrCAR-T Cell Immunotherapy for Leukemia and Lymphoma - May 7

Top banner
ad placement

CELL AND GENE Register for your free weekly newsletter

Manufacturing

Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer - May 8

Donaldson Announces Integrated Lentiviral Vector Manufacturing Platform Development - May 8

Cellpoint Bioservices and Adva Biotechnology Collaborate to Optimize Cell Therapy Manufacturing with the ADVA X3® Platform - May 7

WACKER Expands Production Capacity for Biopharmaceuticals in San Diego - May 6

Takara Bio launches first commercial dissolvable microfluidic lentiviral transduction enhancer - May 6

Middle banner
ad placement

INCLUSION Tackle challenges in diversity, equity, and inclusion with leaders in life sciences. REGISTER NOW

Clinical & Scientific

Bloombury Genetic Therapies Showcases its First Preclinical Data on Parkinson's Disease Program - May 9

Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentation at ASGCT 27th Annual Meeting - May 9

Kate Therapeutics Presented Key Advances in Next-Generation DMD Gene Therapy - May 9

Poseida Therapeutics Highlights Strong Progress on Its Genetic Medicine Programs at the ASGCT 27th Annual Meeting - May 9

Kite And Arctelis Continue Momentum With Advances In Arto-Cel Multiple Myeloma Program - May 9

Epitor Therapeutics Unveils CasNano: A Compact, All-in-One CRISPR/Cas for Single AAV Therapies at the American Society of Gene & Cell Therapy Annual Meeting - May 9

Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing - May 9

Expedited Approval & Orphan Designations

CDER Grants Vacancy Announcement - Physician
AD-0602-Band C, Office of Therapeutic Products (OTP)

Bottom banner
ad placement

Sector Jobs

CDER Grants Vacancy Announcement - Physician
AD-0602-Band C, Office of Therapeutic Products (OTP)

Job placement